Form 4: Amphastar Pharmaceuticals Director Executes Stock Transactions

Director Richard K. Prins of Amphastar Pharmaceuticals executed multiple transactions involving company stock, including option exercises, sales, and a gift.

Summary

• Richard K. Prins, a director at Amphastar Pharmaceuticals, engaged in several stock transactions on November 12, 2024.
• He exercised stock options to acquire 2,500 shares at a price of $16.69 per share.
• He sold 5,000 shares at a weighted average price of $48.7971, with individual sales ranging from $48.797 to $48.95.
• He also gifted 1,000 shares.
• Following these transactions, Mr. Prins directly owns 30,471 shares of Amphastar Pharmaceuticals stock and 4,179 stock options.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions by a company director, with no inherent positive or negative sentiment.

Industry Context

This is a routine SEC Form 4 filing, which is standard for corporate insiders who trade their company's stock. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for directors who may exercise options and sell shares for personal financial management.

Stakeholder Impact

• The transactions may have a minor impact on the stock price, but are generally considered routine for insider trading.
• Shareholders are informed of the director's transactions, promoting transparency.

Key Dates

Keywords

Amphastar Pharmaceuticals, stock transactions, insider trading, stock options, share sales, director, Richard K. Prins